Acadia Pharmaceuticals
$22.35
123
+$0.16+0.72% Tuesday 20:00
Statistics
Day High
22.69
Day Low
22.12
52W High
28.06
52W Low
14.54
Volume
802,828
Avg. Volume
-
Mkt Cap
3.81B
P/E Ratio
9.54
Dividend Yield
-
Dividend
-
Upcoming
Earnings
6MayExpected
Expected EPS
0.050507
Actual EPS
N/A
Financials
36.49%Profit Margin
Profitable2.14BRevenue
782MNet Income
Analyst Ratings
32.75Average Price Target
The highest estimate is 40.00.
From 12 ratings within the last 6 months. This is not an investment recommendation.
From 12 ratings within the last 6 months. This is not an investment recommendation.
Buy 75%
Hold 25%
Sell 0%
People Also Follow
This list is based on the watchlists of people on Stock Events who follow ACAD. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
Johnson & Johnson
JNJ
Mkt Cap546.9B
Lilly(Eli) &
LLY
Mkt Cap862.01B
Novartis
NVS
Mkt Cap279.67B
Pfizer
PFE
Mkt Cap149.77B
Biogen
BIIB
Mkt Cap27.62B
Teva- Pharmaceutical Industries
TEVA
Mkt Cap40.7B
Abbvie
ABBV
Mkt Cap365.43B
Merck
MRK
Mkt Cap277.02B
Alkermes
ALKS
Mkt Cap5.69B
About
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psychosis, and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic, under phase 2 development for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor, under phase 1 development for treating schizophrenia and cognition in Alzheimer's. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
Show more...
CEO
Ms. Catherine E. Owen Adams
Employees
653
Country
United States
ISIN
US0042251084
Listings
0 Comments
Share your thoughts
FAQ
What is Acadia Pharmaceuticals stock price today?▼
The current price of ACAD is $22.35 USD — it has increased by +0.72% in the past 24 hours. Watch Acadia Pharmaceuticals stock price performance more closely on the chart.
What is Acadia Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Acadia Pharmaceuticals stocks are traded under the ticker ACAD.
Is Acadia Pharmaceuticals stock price growing?▼
ACAD stock has risen by +0.68% compared to the previous week, the month change is a +0.13% rise, over the last year Acadia Pharmaceuticals has showed a +53.71% increase.
What is Acadia Pharmaceuticals market cap?▼
Today Acadia Pharmaceuticals has the market capitalization of 3.81B
What is Acadia Pharmaceuticals revenue for the last year?▼
Acadia Pharmaceuticals revenue for the last year amounts to 2.14B USD.
What is Acadia Pharmaceuticals net income for the last year?▼
ACAD net income for the last year is 782M USD.
How many employees does Acadia Pharmaceuticals have?▼
As of May 06, 2026, the company has 653 employees.
In which sector is Acadia Pharmaceuticals located?▼
Acadia Pharmaceuticals operates in the Health & Wellness sector.
When did Acadia Pharmaceuticals complete a stock split?▼
Acadia Pharmaceuticals has not had any recent stock splits.
Where is Acadia Pharmaceuticals headquartered?▼
Acadia Pharmaceuticals is headquartered in San Diego, United States.